Live Breaking News & Updates on உலகளாவிய தலை ஆஃப் ஆராய்ச்சி வளர்ச்சி இல் சனோஃபி

Stay updated with breaking news from உலகளாவிய தலை ஆஃப் ஆராய்ச்சி வளர்ச்சி இல் சனோஃபி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform

Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform
Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda
The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide.
BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) Ten of the world s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. ....

Paul Stoffels , Mikael Dolsten , Kostenloser Wertpapierhandel , Francisco Nogueira , John Reed , Dalvir Gill , Transcelerate Biopharma , Janssen Pharmaceutical Companies Of Johnson , Drug Administration , Research Development At Takeda , Accumulus Synergy Inc , Transcelerate Biopharma Inc , Regulatory Agency , Regulatory Affairs At Roche , Worldwide Research , Global Head Of Research Development At Sanofi , European Medicines Agency , Bristol Myers Squibb , Devices Agency , Accumulus Synergy , Chief Executive Officer , Vice President , Regulatory Affairs , Janssen Pharmaceutical Companies , Japanese Pharmaceutical , Medical Devices Agency ,

Investegate |Accumulus Synergy Announcements | Accumulus Synergy: Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform

Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform
Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda
The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide.
BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. ....

Paul Stoffels , Mikael Dolsten , Francisco Nogueira , John Reed , Dalvir Gill , Transcelerate Biopharma , Janssen Pharmaceutical Companies Of Johnson , Drug Administration , Research Development At Takeda , Accumulus Synergy Inc , Transcelerate Biopharma Inc , Regulatory Agency , Regulatory Affairs At Roche , Worldwide Research , Global Head Of Research Development At Sanofi , European Medicines Agency , Bristol Myers Squibb , Devices Agency , Accumulus Synergy , Develop Global Data Sharing , Chief Executive Officer , Vice President , Regulatory Affairs , Janssen Pharmaceutical Companies , Japanese Pharmaceutical , Medical Devices Agency ,

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects , anticipates , believes , intends , estimates , plans , will be and similar expressions. Although Sanofi s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to ....

United Kingdom , France General , Eva Schaefer Jansen , Arnaud Delepine , Suzanne Greco , Felix Lauscher , Simon Sturge , John Reed , Yvonne Naughton , Brandon Lewis , Fara Berkowitz , Ashleigh Koss , Paul Hudson , Quentin Vivant , Anne Hyland , Global Head Of Research Development At Sanofi , Gotshal Manges , Consilium Strategic Communications , Sanofi Chief Executive , Chief Executive Officer , Eczema Area , Severity Index , Global Head , Hart Scott Rodino Antitrust Improvements Act , Intelliselect Transgenic , Jane Elliott ,